Dynamic path analysis - a useful tool to investigate mediation processes in clinical survival trials

被引:15
|
作者
Strohmaier, Susanne [1 ]
Roysland, Kjetil [1 ]
Hoff, Rune [1 ]
Borgan, Ornulf [2 ]
Pedersen, Terje R. [3 ]
Aalen, Odd O. [1 ]
机构
[1] Univ Oslo, Oslo Ctr Biostat & Epidemiol, Dept Biostat, N-0317 Oslo, Norway
[2] Univ Oslo, Dept Math, N-0317 Oslo, Norway
[3] Univ Oslo, Ulleval Hosp, N-0317 Oslo, Norway
关键词
additive hazard regression; directed acyclic graphs; direct effect; IDEAL study; indirect effect; mediation analysis; survival analysis; MYOCARDIAL-INFARCTION; APOLIPOPROTEIN-B; END-POINTS; CHOLESTEROL; EVENTS; RISK;
D O I
10.1002/sim.6598
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
When it comes to clinical survival trials, regulatory restrictions usually require the application of methods that solely utilize baseline covariates and the intention-to-treat principle. Thereby, much potentially useful information is lost, as collection of time-to-event data often goes hand in hand with collection of information on biomarkers and other internal time-dependent covariates. However, there are tools to incorporate information from repeated measurements in a useful manner that can help to shed more light on the underlying treatment mechanisms. We consider dynamic path analysis, a model for mediation analysis in the presence of a time-to-event outcome and time-dependent covariates to investigate direct and indirect effects in a study of different lipid-lowering treatments in patients with previous myocardial infarctions. Further, we address the question whether survival in itself may produce associations between the treatment and the mediator in dynamic path analysis and give an argument that because of linearity of the assumed additive hazard model, this is not the case. We further elaborate on our view that, when studying mediation, we are actually dealing with underlying processes rather than single variables measured only once during the study period. This becomes apparent in results from various models applied to the study of lipid-lowering treatments as well as our additionally conducted simulation study, where we clearly observe that discarding information on repeated measurements can lead to potentially erroneous conclusions. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:3866 / 3887
页数:22
相关论文
共 25 条
  • [21] Liver resection had better disease-free survival rates compared with radiofrequency ablation in hepatocellular carcinoma: a meta-analysis based on randomized clinical trials
    Yeo, Yee-Hui
    Kang, Yi-No
    Chen, Chiehfeng
    Lee, Teng-Yu
    Yeh, Chun-Chieh
    Huang, Tsai-Wei
    Wu, Chun-Ying
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (11) : 7225 - 7233
  • [22] Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
    Paolo A. Ascierto
    Antoni Ribas
    James Larkin
    Grant A. McArthur
    Karl D. Lewis
    Axel Hauschild
    Keith T. Flaherty
    Edward McKenna
    Qian Zhu
    Yong Mun
    Brigitte Dréno
    Journal of Translational Medicine, 18
  • [23] Impact of spleen-preserving total gastrectomy on postoperative infectious complications and 5-year overall survival: systematic review and meta-analysis of contemporary randomized clinical trials
    Aiolfi, A.
    Asti, E.
    Siboni, S.
    Bernardi, D.
    Rausa, E.
    Bonitta, G.
    Bonavina, L.
    CURRENT ONCOLOGY, 2019, 26 (02) : E202 - E209
  • [24] Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials
    Hess, Paul L.
    Laird, Amy
    Edwards, Rex
    Bardy, Gust H.
    Bigger, J. Thomas
    Buxton, Alfred E.
    Moss, Arthur J.
    Lee, Kerry L.
    Hall, W. J.
    Steinman, Richard
    Dorian, Paul
    Al Hallstrom
    Cappato, Riccardo
    Kadish, Alan H.
    Kudenchuk, Peter J.
    Mark, Daniel B.
    Al-Khatib, Sana M.
    Piccini, Jonathan P.
    Inoue, Lurdes Y. T.
    Sanders, Gillian D.
    HEART RHYTHM, 2013, 10 (06) : 828 - 835
  • [25] Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
    Jain, Preetesh
    Kantarjian, Hagop
    Alattar, Mona Lisa
    Jabbour, Elias
    Sasaki, Koji
    Gonzalez, Graciela Nogueras
    Dellasala, Sara
    Pierce, Sherry
    Verstovsek, Srdan
    Wierda, William
    Borthakur, Gautam
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge
    LANCET HAEMATOLOGY, 2015, 2 (03): : E118 - E128